DJIA 16,501.65 0.00 0.00%
NASDAQ 4,148.34 0.00 0.00%
S&P 500 1,878.61 3.22 0.17%
market minute promo

MannKind Corp

NASDAQ: MNKD

6.38 0.02 (0.31%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

MNKD $6.38 0.31%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $6.43
Previous Close $6.36
Daily Range $6.23 - $6.48
52-Week Range $3.76 - $8.70
Market Cap $2.4B
P/E Ratio -9.94
Dividend (Yield) $0.00 (0.0%)
Volume 5,004,034
Average Daily Volume 14,213,669
Current FY EPS -$0.31

Sector

Healthcare

Industry

Drugs

MannKind Corp (MNKD) Description

A biopharmaceutical company focused on the development and commercialization of therapeutic products for diseases such as diabetes and cancer. Website: http://www.mannkindcorp.com/

News & Commentary

5 Questions for MannKind

The inhaled insulin drugmaker faces an FDA review in April, but when will AstraZeneca, Merck or one of the other major drugmakers step up and license Afrezza?

Bulls Hold the Reins as Winning Streak Continues

Cramer's Lightning Round - I Am Critical And Skeptical Of MannKind (4/17/14)

XBI, MNKD, UTHR, ARNA: Large Inflows Detected at ETF

MannKind (MNKD) Stock Continues Decline Today

The Stalled State Of MannKind

One Factor Driving MannKind (MNKD) Stock Down Today

MannKind Rival, Also Developing Inhaled Insulin Device, Files $75M IPO

Why I Believe MannKind Shares Will Rise Significantly Upon FDA Approval Of Afrezza

Company News for April 08, 2014 - Corporate Summary

UPDATE: Brinson Patrick Initiates Coverage on MannKind

See More MNKD News...

MNKD's Top Competitors

MNKD $6.38 (0.31%)
Current stock: MNKD
CELG $141.25 (-2.47%)
Current stock: CELG
AMGN $113.72 (0.36%)
Current stock: AMGN
BIIB $294.84 (-3.88%)
Current stock: BIIB